Analysts
Most recent initiations
| TopoTarget | Addex Pharmaceuticals |
| Consort Medical | Evotec |
| ProMetic Life Sciences | ProStrakan |
Recent QuickViews
Shire
Win-win situation
Pharmaceutical & Healthcare | published 04/08/2010
Immunodiagnostic Systems Holdings
Highly rated bet
Pharmaceutical & Healthcare | published 14/07/2010
Galapagos
Continued evolution
Pharmaceutical & Healthcare | published 23/03/2010
Epigenomics AG
Positiver Ausblick
Pharmaceutical & Healthcare | published 10/03/2010
Would you like to be notified when new research is published? Access our research RSS feed
Healthcare sector team
Latest research
TopoTarget
Betting on belinostat
Outlook | Pharmaceutical & Healthcare | 10/09/2010TopoTarget’s prospects are closely tied to those of its lead drug, belinostat. It is in a pivotal Phase II trial for peripheral T-cell lymphoma (PTCL)…
Addex Pharmaceuticals
R&D progress
Review | Pharmaceutical & Healthcare | 09/09/2010Addex continues to make good progress in R&D as it moves towards the initiation of Phase II studies of ADX48621 in Parkinson’s disease levodopa-induced…
Biocompatibles
Consistent profit basis
Review | Pharmaceutical & Healthcare | 09/09/2010Interim results (revenues £17m, net profit £1.2m) confirm that Biocompatibles now expects to be consistently profitable. There will still be occasional…
BTG
Specialty pharma transition
Review | Pharmaceutical & Healthcare | 08/09/2010BTG is on track to complete its planned evolution into a speciality pharma business later this month and begin marketing CroFab and DigiFab from 1 October.…
Pharming Group
FDA sets a BLA route
Update | Pharmaceutical & Healthcare | 27/08/2010The FDA and Pharming have reached a conclusion about the Ruconest regulatory pathway allowing a Biological License Application to be made before January…
Research methodology
Edison has significant expertise in analysing companies involved in the biotech, med-tech and diagnostic sub-sectors of the healthcare industry. We have a particular strength in biotech, where our approach combines rigorous financial analysis with detailed scientific appraisal of the merits of individual development programmes and the risks (scientific, regulatory and market) associated with them. We put particular attention on competitive dynamics within therapeutic areas and focus on evaluating the results of clinical trials. Sales projections are usually derived from epidemiologically-based models. We generally value companies on the basis of a risk-adjusted net present value of the cash flows that may be available under (real and hypothetical) licensing deals. As a result, we closely follow industry trends regarding biotech-pharma licensing deals.
Sector reports
Sectors covered
Pharmaceutical & Healthcare Show companies
- Abcam
- Actelion
- Addex Pharmaceuticals
- Agennix AG
- AGI Therapeutics
- Algeta
- Allergy Therapeutics
- Alliance Pharma
- Antisoma
- Arena Pharmaceuticals
- Ark Therapeutics Group
- Assura Group
- Asterand
- AstraZeneca
- Avacta
- Biocompatibles
- Bionomics
- Biotie Therapies Corp
- BTG
- CareTech
- ClearStream Technologies Group
- Consort Medical
- Cryo-Save Group
- Cyprotex
- Deltex Medical
- Eco Animal Health
- Epigenomics AG
- Epistem Holdings
- Evotec
- Futura Medical
- Galapagos
- GlaxoSmithKline
- GW Pharmaceuticals
- Immunodiagnostic Systems Holdings
- ImmuPharma
- IS Pharma
- Lifeline Scientific
- Lombard Medical Technologies
- MDY Healthcare
- Medcom Tech
- Merrion Pharmaceuticals
- Minster Pharmaceuticals
- Neuropharm
- NeuroSearch
- NextGen Sciences
- Omega Diagnostics Group
- Oncolytics Biotech Inc
- Optos
- Orexigen
- Oxford BioMedica
- Paion
- Pharming Group
- Phytopharm
- Plethora Solutions Holdings
- ProMetic Life Sciences
- ProStrakan
- Proximagen Group
- ReGen Therapeutics
- Renovo
- Sareum Holdings
- Shire
- Sinclair Pharma
- SkyePharma
- Smith & Nephew
- Sosei Group Corporation
- SuperGen
- TopoTarget
- Vectura
- Vernalis
- Vindon Healthcare
- Vivus
- WaferGen Biosystems
- Wilex
- YM BioSciences
